Product Description
Chimeric IgG_1 monoclonal antibodyCSL360 recognizes the CD123"+/CD131" phenotype expressed by leukemic stem cells (LSC).
Mechanisms of Action: CD123 Antagonist
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CSL Limited
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Acute Myeloid Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00401739 |
CSLCT-AML-06-26 | P1 |
Completed |
Acute Myeloid Leukemia |
2009-09-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|